medigraphic.com
ISSN 0185-3252 (Print)
Revista de la Asociación Médica del Centro Médico ABC

2020, Number 2

<< Back

An Med Asoc Med Hosp ABC 2020; 65 (2)

Hemolytic anemia in the newborn secondary to subgroup Kell incompatibility

Crespo SD, Septién GJM, Ortiz ROE

Language: Spanish
References: 12
Page: 158-161
PDF size: 215.60 Kb.


ABSTRACT

The anemia of the newborn can be from different causes, one of them is the hemolytic anemia of the newborn which can be secondary to Rh o ABO incompatibility, however there exist other subgroups that can cause incompatibility and secondary hemolityc anemia, jaundice and hyperbilirubinemia. This one presents with less frequency and may result in progressive anemia and it requires attention of the newborn in a neonatal intensive care unit. Case report: This work describes the case of a pale newborn with poor respiratory effort and low oxygen rates, with anemia, hyperbilirubinemia and hepatomegaly who requires exchange transfusion and evaluation of the hematologist who found incompatibility to subgroup Kell. Most of the cases due to subgroup Kell incompatibility present a severe hemolytic anemia with a fatal evolution and not a good prognosis. Conclusion: In this report we can see that the newborn had a satisfactory evolution due to prompt treatment and the importance of knowing different causes of hemolytic anemia of the newborn.


REFERENCES

  1. Gleason C, Juul S. Avery’s diseases of the newborn. 10th ed. Philadelphia, PA: Elsevier; 2018.

  2. Garratty G. Drug-induced immune hemolytic anemia. Hematology Am Soc Hematol Educ Program. 2009; 73-79.

  3. Zuñiga M, Varela J, Valero M, Novik V, Peña C. Ictericia e Incompatibilidad por grupo Kell: caso clínico. CIMEL. 2009; 14 (2): 116-119.

  4. Denomme GA. Kell and Kx blood group systems. Inmunohmatology. 2015; 31 (1): 14-19.

  5. Karagol BS, Zenciroglu A, Okumus N, Karadag N, Dursun A, Hakan N. Hemolytic disease of the newborn caused by irregular blood subgroup (Kell, C, c, E, and e) incompatibilities: report of 106 cases at a tertiary-care centre. Am J Perinatol. 2012; 29 (6): 449-454.

  6. Vásquez Rojas M, Castillo Espinosa D, Pavez Espinoza Y, Maldonado Rojas M, Mena Leiva A. Frecuencia de antígenos del sistema sanguíneo Rh y del sistema Kell en donantes de sangre. Rev Cubana Hematol Inmunol Hemoter. 2015; 31 (2): 160-171.

  7. Scharberg EA, Wieckhusen C, Luz B, et al. Fatal hemolytic disease of the newborn caused by an antibody to KEAL, a new low-prevalence Kell blood group antigen. Transfusion. 2017; 57 (1): 217-218.

  8. Aristizábal JM, Torres JD. Transfusiones en pacientes con pruebas de compatibilidad positivas y en aquellos con anemia hemolítica autoinmune. IATREIA. 2007; 2 (4): 379-387.

  9. Romero D, Hernández J. Enfermedad Hemolítica del recién nacido. Rev Med Inst Mex Seguro Soc. 2005; 4 3(S1): 33-36.

  10. Slootweg YM, Lindenburg IT, Koelewijn JM, Van Kamp IL, Oepkes D, De Haas M. Predicting anti-Kell-mediated hemolytic disease of the fetus and newborn: diagnostic accuracy of laboratory management. Am J Obstet Gynecol. 2018; 219 (4): 393.e1-393.e8.

  11. Diagnóstico y tratamiento de la enfermedad hemolítica por isoinmunización a Rh en el recién nacido. Guía de Evidencias y Recomendaciones: Guía de Práctica Clínica. México, CENETEC; 2018.

  12. Mattaloni SM, Amoni C, Céspedes R, Nonaka C, Trucco Boggione C, Luján Brajovich ME et al. Clinical significance of an alloantibody against the Kell blood group glycoprotein. Transfus Med Hemother. 2017; 44 (1): 53-57.




2020     |     www.medigraphic.com